EIM
CRL icon

Essex Investment Management’s Charles River Laboratories CRL Stock Holding History

Essex Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,198
Closed -$847K – 380
2023
Q1 		$847K Buy
+4,198
New +$951K 0.12% 217
2015
Q3 		– Sell
-11,179
Closed -$786K – 322
2015
Q2 		$786K Sell
11,179
-895
-7% -$66.2K 0.12% 186
2015
Q1 		$957K Buy
12,074
+5,889
+95% +$434K 0.13% 161
2014
Q4 		$394K Hold
6,185
– – 0.06% 254
2014
Q3 		$369K Sell
6,185
-1,415
-19% -$81K 0.06% 264
2014
Q2 		$407K Buy
+7,600
New +$417K 0.06% 266

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Essex Investment Management's CRL Position: Q2 2023 in Review

Essex Investment Management sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 4,198 shares — an estimated $847K sold.

Essex Investment Management first reported a position in CRL in Q2 2014 and held it in 6 quarters. The position peaked at $957K in Q1 2015. 613 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Essex Investment Management reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Essex Investment Management sold 4,198 Charles River Laboratories shares in Q2 2023, an estimated $847K.
  • Essex Investment Management first reported a position in Charles River Laboratories in Q2 2014 and held it in 6 quarters.
  • Essex Investment Management's Charles River Laboratories position peaked at $957K in Q1 2015.
  • 613 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Essex Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.